Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
To date, no specific treatment has been established to reverse progressive chronic kidney disease (CKD). To evaluate the safety and efficacy of autologous CD34+ cell transplantation in CKD patients who exhibited a progressive decline in renal function, we performed a pilot clinical trial of regenerative therapy using autologous CD34+ cells in patients with progressive CKD.
A clinical trial of autologous CD34+ cell therapy for progressive CKD with inclusion criteria of estimated glomerular filtration rate (eGFR) 15–45 mL/minute/1.73 m2 (CKD stage G3a–G4) was performed. After five days of treatment with the granulocyte colony-stimulating factor, mononuclear cells were harvested and CD34+ cells were magnetically collected. CD34+ cells (1×106/kg) were directly injected into the bilateral renal arteries twice (at zero and three months), and their safety and efficacy were evaluated for 6 months.
Four patients were enrolled and completed the study. The eGFR levels at study entry was 15-28 mL/minute/1.73 m2. Three of four patients showed improvement in eGFR slope (eGFR slope > 0 mL/minute/1.73 m2), with the monthly slope of eGFR (delta eGFR) changing from -1.36 ± 1.1 (pretreatment) to +0.22 ± 0.71 (at 6 months) mL/minute/1.73 m2/month (P = 0.135) after cell therapy. Additionally, intrarenal resistive index (P = 0.004) and shear wave velocity (P = 0.04) were significantly improved after cell therapy. No severe adverse events were reported.
Our findings suggest that repetitive peripheral blood-derived autologous CD34+ cell transplantation into the renal arteries is safe, feasible, and may be effective for patients with progressive CKD. Renal function improvement was accompanied by intra-renal microcirculatory improvement. A largescale clinical trial is warranted to validate the efficacy of cell therapy. We are now performing next step clinical trial of this cell therapy by expanding the subjects with eGFR less than 60 mL/min/1.73m2, but not on hemodialysis (CKD stage G3a-G5).
